UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Alternative renal replacement therapies in end-stage renal disease

Authors
Andreas Pierratos, MD, FRCPC
Gihad E Nesrallah, MD, MSc, FRCPC, FACP
Section Editor
Jeffrey S Berns, MD
Deputy Editor
Alice M Sheridan, MD

INTRODUCTION

Despite improvements in technology and general medical care, the mortality rate of patients on maintenance dialysis remains alarmingly high, at approximately 15 to 20 percent per year [1,2]. In an attempt to improve outcomes, it was postulated that a higher dialysis dose than commonly provided during conventional dialysis may increase survival among patients undergoing renal replacement therapies [3].

However, this hypothesis was refuted in two large, well-designed studies in both hemodialysis and peritoneal dialysis patients:

The Hemodialysis (HEMO) Study found no improvement in patient survival when per-session hemodialysis dose was increased above the Kidney Disease Outcomes Quality Initiative (KDOQI) recommendations [4]. (See "Prescribing and assessing adequate hemodialysis".)

In the Adequacy of Peritoneal Dialysis in Mexico (ADEMEX) study, no reduction in mortality was seen with peritoneal dialysis doses greater than a weekly Kt/V of 1.7 [5]. (See "Prescribing and assessing adequate peritoneal dialysis".)

In the wake of these negative trials, more attention has turned to alternative dialysis schedules, including long intermittent hemodialysis, short daily hemodialysis, and nocturnal hemodialysis. Each of these approaches is discussed in detail separately. (See "Technical aspects of nocturnal hemodialysis" and "Short daily hemodialysis".)

                                       

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Thu Jan 28 00:00:00 GMT 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. USRDS: The United States Renal Data System: Overall hospitalization and mortality. Am J Kidney Dis 2010; 55(Suppl 1):S1.
  2. USRDS. Morbidity and mortality. http://www.usrds.org (Accessed on February 10, 2009).
  3. Lowrie E, Laird NM. National Cooperative Dialysis Study. Kidney Int Suppl 1983; 23:19.
  4. Eknoyan G, Beck GJ, Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347:2010.
  5. Paniagua R, Amato D, Vonesh E, et al. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 2002; 13:1307.
  6. Vanholder R, De Smet R, Glorieux G, et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003; 63:1934.
  7. Lowrie EG, Laird NM, Parker TF, Sargent JA. Effect of the hemodialysis prescription of patient morbidity: report from the National Cooperative Dialysis Study. N Engl J Med 1981; 305:1176.
  8. Yavuz A, Tetta C, Ersoy FF, et al. Uremic toxins: a new focus on an old subject. Semin Dial 2005; 18:203.
  9. Vanholder R, Glorieux G, Lameire N, European Uremic Toxin Work Group. Uraemic toxins and cardiovascular disease. Nephrol Dial Transplant 2003; 18:463.
  10. Huang Z, Gao D, Henderson LW, Clark WR. Hemofiltration and hemodiafiltration for end stage renal disease. In: Chronic Kidney Disease, Dialysis, and Transplantation. Companion to Brenner and Rector's The Kidney, 2nd ed., Pereira BJG, Sayegh MK, Blake P (Eds), Elsevier Saunders, Philadelphia 2006. p.481.
  11. Tattersall JE, Ward RA, EUDIAL group. Online haemodiafiltration: definition, dose quantification and safety revisited. Nephrol Dial Transplant 2013; 28:542.
  12. Wizemann V, Külz M, Techert F, Nederlof B. Efficacy of haemodiafiltration. Nephrol Dial Transplant 2001; 16 Suppl 4:27.
  13. Shinzato T, Sezaki R, Usuda M, et al. Infusion-free hemodiafiltration: simultaneous hemofiltration and dialysis with no need for infusion fluid. Artif Organs 1982; 6:453.
  14. Miwa M, Shinzato T. Push/pull hemodiafiltration: technical aspects and clinical effectiveness. Artif Organs 1999; 23:1123.
  15. Maeda K, Kobayakawa H, Fujita Y, et al. Effectiveness of push/pull hemodiafiltration using large-pore membrane for shoulder joint pain in long-term dialysis patients. Artif Organs 1990; 14:321.
  16. Basile C, Giordano R, Montanaro A, et al. Effect of acetate-free biofiltration on the anaemia of haemodialysis patients: a prospective cross-over study. Nephrol Dial Transplant 2001; 16:1914.
  17. Schrander-vd Meer AM, ter Wee PM, Kan G, et al. Improved cardiovascular variables during acetate free biofiltration. Clin Nephrol 1999; 51:304.
  18. Todeschini M, Macconi D, Fernández NG, et al. Effect of acetate-free biofiltration and bicarbonate hemodialysis on neutrophil activation. Am J Kidney Dis 2002; 40:783.
  19. Verzetti G, Navino C, Bolzani R, et al. Acetate-free biofiltration versus bicarbonate haemodialysis in the treatment of patients with diabetic nephropathy: a cross-over multicentric study. Nephrol Dial Transplant 1998; 13:955.
  20. Stenvinkel P. Inflammation in end-stage renal disease--a fire that burns within. Contrib Nephrol 2005; 149:185.
  21. Kjellstrand CM, Kjellstrand P. The ideal home hemodialysis machine. Hemodial Int 2008; 12 Suppl 1:S33.
  22. Henderson LW, Beans E. Successful production of sterile pyrogen-free electrolyte solution by ultrafiltration. Kidney Int 1978; 14:522.
  23. Ledebo I. On-line hemodiafiltration: technique and therapy. Adv Ren Replace Ther 1999; 6:195.
  24. Ledebo I. On-line preparation of solutions for dialysis: practical aspects versus safety and regulations. J Am Soc Nephrol 2002; 13 Suppl 1:S78.
  25. Vaslaki L, Karátson A, Vörös P, et al. Can sterile and pyrogen-free on-line substitution fluid be routinely delivered? A multicentric study on the microbiological safety of on-line haemodiafiltration. Nephrol Dial Transplant 2000; 15 Suppl 1:74.
  26. Tattersall J, Martin-Malo A, Pedrini L, et al. EBPG guideline on dialysis strategies. Nephrol Dial Transplant 2007; 22 Suppl 2:ii5.
  27. Davenport A, Peters SA, Bots ML, et al. Higher convection volume exchange with online hemodiafiltration is associated with survival advantage for dialysis patients: the effect of adjustment for body size. Kidney Int 2016; 89:193.
  28. Mostovaya IM, Grooteman MP, Basile C, et al. High convection volume in online post-dilution haemodiafiltration: relevance, safety and costs. Clin Kidney J 2015; 8:368.
  29. Chapdelaine I, de Roij van Zuijdewijn CL, Mostovaya IM, et al. Optimization of the convection volume in online post-dilution haemodiafiltration: practical and technical issues. Clin Kidney J 2015; 8:191.
  30. Maduell F, Ojeda R, Arias-Guillén M, et al. Optimization of dialysate flow in on-line hemodiafiltration. Nefrologia 2015; 35:473.
  31. Canaud B, Barbieri C, Marcelli D, et al. Optimal convection volume for improving patient outcomes in an international incident dialysis cohort treated with online hemodiafiltration. Kidney Int 2015; 88:1108.
  32. Penne EL, van der Weerd NC, Bots ML, et al. Patient- and treatment-related determinants of convective volume in post-dilution haemodiafiltration in clinical practice. Nephrol Dial Transplant 2009; 24:3493.
  33. Ward RA. Protein-leaking membranes for hemodialysis: a new class of membranes in search of an application? J Am Soc Nephrol 2005; 16:2421.
  34. Ronco C, Crepaldi C, Brendolan A, et al. Evolution of synthetic membranes for blood purification: the case of the Polyflux family. Nephrol Dial Transplant 2003; 18 Suppl 7:vii10.
  35. Ronco C, Breuer B, Bowry SK. Hemodialysis membranes for high-volume hemodialytic therapies: the application of nanotechnology. Hemodial Int 2006; 10 Suppl 1:S48.
  36. Ronco C. Hemodiafiltration: Technical and Clinical Issues. Blood Purif 2015; 40 Suppl 1:2.
  37. Ghysen J, De Plaen JF, van Ypersele de Strihou C. The effect of membrane characteristics on tumour necrosis factor kinetics during haemodialysis. Nephrol Dial Transplant 1990; 5:270.
  38. Canivet E, Lavaud S, Wong T, et al. Cuprophane but not synthetic membrane induces increases in serum tumor necrosis factor-alpha levels during hemodialysis. Am J Kidney Dis 1994; 23:41.
  39. Schindler R, Lonnemann G, Schäffer J, et al. The effect of ultrafiltered dialysate on the cellular content of interleukin-1 receptor antagonist in patients on chronic hemodialysis. Nephron 1994; 68:229.
  40. Bommer J, Jaber BL. Ultrapure dialysate: facts and myths. Semin Dial 2006; 19:115.
  41. Canaud B, Bosc JY, Leblanc M, et al. Evaluation of high-flux hemodiafiltration efficiency using an on-line urea monitor. Am J Kidney Dis 1998; 31:74.
  42. Canaud B, Bragg-Gresham JL, Marshall MR, et al. Mortality risk for patients receiving hemodiafiltration versus hemodialysis: European results from the DOPPS. Kidney Int 2006; 69:2087.
  43. Pedrini LA, De Cristofaro V, Comelli M, et al. Long-term effects of high-efficiency on-line haemodiafiltration on uraemic toxicity. A multicentre prospective randomized study. Nephrol Dial Transplant 2011; 26:2617.
  44. Maduell F, del Pozo C, Garcia H, et al. Change from conventional haemodiafiltration to on-line haemodiafiltration. Nephrol Dial Transplant 1999; 14:1202.
  45. Lornoy W, Becaus I, Billiouw JM, et al. Remarkable removal of beta-2-microglobulin by on-line hemodiafiltration. Am J Nephrol 1998; 18:105.
  46. Ward RA, Schmidt B, Hullin J, et al. A comparison of on-line hemodiafiltration and high-flux hemodialysis: a prospective clinical study. J Am Soc Nephrol 2000; 11:2344.
  47. Shinzato T, Kobayakawa H, Maeda K. Comparison of various treatment modes in terms of beta 2-microglobulin removal: hemodialysis, hemofiltration, and push/pull HDF. Artif Organs 1989; 13:66.
  48. Maduell F, Navarro V, Cruz MC, et al. Osteocalcin and myoglobin removal in on-line hemodiafiltration versus low- and high-flux hemodialysis. Am J Kidney Dis 2002; 40:582.
  49. Canaud B, Assounga A, Kerr P, et al. Failure of a daily haemofiltration programme using a highly permeable membrane to return beta 2-microglobulin concentrations to normal in haemodialysis patients. Nephrol Dial Transplant 1992; 7:924.
  50. Susantitaphong P, Siribamrungwong M, Jaber BL. Convective therapies versus low-flux hemodialysis for chronic kidney failure: a meta-analysis of randomized controlled trials. Nephrol Dial Transplant 2013; 28:2859.
  51. Wang AY, Ninomiya T, Al-Kahwa A, et al. Effect of hemodiafiltration or hemofiltration compared with hemodialysis on mortality and cardiovascular disease in chronic kidney failure: a systematic review and meta-analysis of randomized trials. Am J Kidney Dis 2014; 63:968.
  52. Nistor I, Palmer SC, Craig JC, et al. Convective versus diffusive dialysis therapies for chronic kidney failure: an updated systematic review of randomized controlled trials. Am J Kidney Dis 2014; 63:954.
  53. Zehnder C, Gutzwiller JP, Renggli K. Hemodiafiltration--a new treatment option for hyperphosphatemia in hemodialysis patients. Clin Nephrol 1999; 52:152.
  54. Minutolo R, Bellizzi V, Cioffi M, et al. Postdialytic rebound of serum phosphorus: pathogenetic and clinical insights. J Am Soc Nephrol 2002; 13:1046.
  55. Penne EL, van der Weerd NC, van den Dorpel MA, et al. Short-term effects of online hemodiafiltration on phosphate control: a result from the randomized controlled Convective Transport Study (CONTRAST). Am J Kidney Dis 2010; 55:77.
  56. Davenport A, Gardner C, Delaney M, Pan Thames Renal Audit Group. The effect of dialysis modality on phosphate control : haemodialysis compared to haemodiafiltration. The Pan Thames Renal Audit. Nephrol Dial Transplant 2010; 25:897.
  57. Beerenhout CH, Luik AJ, Jeuken-Mertens SG, et al. Pre-dilution on-line haemofiltration vs low-flux haemodialysis: a randomized prospective study. Nephrol Dial Transplant 2005; 20:1155.
  58. Lin CL, Huang CC, Yu CC, et al. Reduction of advanced glycation end product levels by on-line hemodiafiltration in long-term hemodialysis patients. Am J Kidney Dis 2003; 42:524.
  59. Gerdemann A, Wagner Z, Solf A, et al. Plasma levels of advanced glycation end products during haemodialysis, haemodiafiltration and haemofiltration: potential importance of dialysate quality. Nephrol Dial Transplant 2002; 17:1045.
  60. Widjaja A, Kielstein JT, Horn R, et al. Free serum leptin but not bound leptin concentrations are elevated in patients with end-stage renal disease. Nephrol Dial Transplant 2000; 15:846.
  61. Calò LA, Naso A, Carraro G, et al. Effect of haemodiafiltration with online regeneration of ultrafiltrate on oxidative stress in dialysis patients. Nephrol Dial Transplant 2007; 22:1413.
  62. Vaslaki LR, Berta K, Major L, et al. On-line hemodiafiltration does not induce inflammatory response in end-stage renal disease patients: results from a multicenter cross-over study. Artif Organs 2005; 29:406.
  63. Altieri P, Sorba GB, Bolasco PG, et al. On-line predilution hemofiltration versus ultrapure high-flux hemodialysis: a multicenter prospective study in 23 patients. Sardinian Collaborative Study Group of On-Line Hemofiltration. Blood Purif 1997; 15:169.
  64. Altieri P, Sorba G, Bolasco P, et al. Predilution haemofiltration--the Second Sardinian Multicentre Study: comparisons between haemofiltration and haemodialysis during identical Kt/V and session times in a long-term cross-over study. Nephrol Dial Transplant 2001; 16:1207.
  65. Mion M, Kerr PG, Argiles A, et al. Haemodiafiltration in high-cardiovascular-risk patients. Nephrol Dial Transplant 1992; 7:453.
  66. Donauer J, Schweiger C, Rumberger B, et al. Reduction of hypotensive side effects during online-haemodiafiltration and low temperature haemodialysis. Nephrol Dial Transplant 2003; 18:1616.
  67. Locatelli F, Altieri P, Andrulli S, et al. Hemofiltration and hemodiafiltration reduce intradialytic hypotension in ESRD. J Am Soc Nephrol 2010; 21:1798.
  68. Locatelli F, Mastrangelo F, Redaelli B, et al. Effects of different membranes and dialysis technologies on patient treatment tolerance and nutritional parameters. The Italian Cooperative Dialysis Study Group. Kidney Int 1996; 50:1293.
  69. Karamperis N, Jensen D, Sloth E, Jensen JD. Comparison of predilution hemodiafiltration and low-flux hemodialysis at temperature-controlled conditions using high calcium-ion concentration in the replacement and dialysis fluid. Clin Nephrol 2007; 67:230.
  70. Pinney JH, Oates T, Davenport A. Haemodiafiltration does not reduce the frequency of intradialytic hypotensive episodes when compared to cooled high-flux haemodialysis. Nephron Clin Pract 2011; 119:c138.
  71. Di Filippo S, Manzoni C, Andrulli S, et al. Sodium removal during pre-dilution haemofiltration. Nephrol Dial Transplant 2003; 18 Suppl 7:vii31.
  72. Di Filippo S, Manzoni C, Andrulli S, et al. Sodium removal during pre-dilution haemofiltration. Nephrol Dial Transplant 2003; 18 Suppl 7:vii31.
  73. Karamperis N, Sloth E, Jensen JD. Predilution hemodiafiltration displays no hemodynamic advantage over low-flux hemodialysis under matched conditions. Kidney Int 2005; 67:1601.
  74. Kjellstrand CM, Blagg CR, Twardowski ZJ, Bower J. Cardiovascular stability (CVI) during daily hemodialysis (DHD) - Relative influence of dialysis purity, clearance and ultrafiltration speed - Experience with the Aksys PHD system. ASAIO J 2004; 50:177.
  75. Kjellstrand C, Blagg C, Odar-Cederlof I, et al. Daily hemodialysis (DHD) and ultrapure dialysis (UPH) synergistically improve patient well-being (WB) and cardiovascular stability (CVS). Hemodial Int 2007; 11:104.
  76. Schünemann B, Girndt J, Quellhorst E. Hemofiltration as a treatment for "dialysis-resistant" hypertension and hypotensive hyperhydration. J Dial 1977; 1:575.
  77. Kishimoto T, Yamagami S, Tanaka H, et al. Superiority of hemofiltration to hemodialysis for treatment of chronic renal failure: comparative studies between hemofiltration and hemodialysis on dialysis disequilibrium syndrome. Artif Organs 1980; 4:86.
  78. Alvestrand A, Ledebo I, Hagerman I, et al. Left ventricular hypertrophy in incident dialysis patients randomized to treatment with hemofiltration or hemodialysis: results from the ProFil study. Blood Purif 2011; 32:21.
  79. Rabindranath KS, Strippoli GF, Daly C, et al. Haemodiafiltration, haemofiltration and haemodialysis for end-stage kidney disease. Cochrane Database Syst Rev 2006; :CD006258.
  80. Bonforte G, Grillo P, Zerbi S, Surian M. Improvement of anemia in hemodialysis patients treated by hemodiafiltration with high-volume on-line-prepared substitution fluid. Blood Purif 2002; 20:357.
  81. Lin CL, Huang CC, Yu CC, et al. Improved iron utilization and reduced erythropoietin resistance by on-line hemodiafiltration. Blood Purif 2002; 20:349.
  82. Vaslaki L, Major L, Berta K, et al. On-line haemodiafiltration versus haemodialysis: stable haematocrit with less erythropoietin and improvement of other relevant blood parameters. Blood Purif 2006; 24:163.
  83. Wizemann V, Lotz C, Techert F, Uthoff S. On-line haemodiafiltration versus low-flux haemodialysis. A prospective randomized study. Nephrol Dial Transplant 2000; 15 Suppl 1:43.
  84. Hsu PY, Lin CL, Yu CC, et al. Ultrapure dialysate improves iron utilization and erythropoietin response in chronic hemodialysis patients - a prospective cross-over study. J Nephrol 2004; 17:693.
  85. Guth HJ, Gruska S, Kraatz G. On-line production of ultrapure substitution fluid reduces TNF-alpha- and IL-6 release in patients on hemodiafiltration therapy. Int J Artif Organs 2003; 26:181.
  86. Sitter T, Bergner A, Schiffl H. Dialysate related cytokine induction and response to recombinant human erythropoietin in haemodialysis patients. Nephrol Dial Transplant 2000; 15:1207.
  87. Kleophas W, Haastert B, Backus G, et al. Long-term experience with an ultrapure individual dialysis fluid with a batch type machine. Nephrol Dial Transplant 1998; 13:3118.
  88. Lamas JM, Alonso M, Sastre F, et al. Ultrapure dialysate and inflammatory response in haemodialysis evaluated by darbepoetin requirements--a randomized study. Nephrol Dial Transplant 2006; 21:2851.
  89. Penne EL, Blankestijn PJ, Bots ML, et al. Resolving controversies regarding hemodiafiltration versus hemodialysis: the Dutch Convective Transport Study. Semin Dial 2005; 18:47.
  90. Grooteman MP, van den Dorpel MA, Bots ML, et al. Effect of online hemodiafiltration on all-cause mortality and cardiovascular outcomes. J Am Soc Nephrol 2012; 23:1087.
  91. O'Loughlin JA, Bruder JM, Lysaght MJ. Degradation of low molecular weight uremic solutes by oral delivery of encapsulated enzymes. ASAIO J 2004; 50:253.
  92. Lin CL, Huang CC, Chang CT, et al. Clinical improvement by increased frequency of on-line hemodialfiltration. Ren Fail 2001; 23:193.
  93. Rabindranath KS, Strippoli GF, Roderick P, et al. Comparison of hemodialysis, hemofiltration, and acetate-free biofiltration for ESRD: systematic review. Am J Kidney Dis 2005; 45:437.
  94. Cross J, Davenport A. Does online hemodiafiltration lead to reduction in trace elements and vitamins? Hemodial Int 2011; 15:509.
  95. Morena M, Cristol JP, Bosc JY, et al. Convective and diffusive losses of vitamin C during haemodiafiltration session: a contributive factor to oxidative stress in haemodialysis patients. Nephrol Dial Transplant 2002; 17:422.
  96. Cheung AK, Rocco MV, Yan G, et al. Serum beta-2 microglobulin levels predict mortality in dialysis patients: results of the HEMO study. J Am Soc Nephrol 2006; 17:546.
  97. Maduell F, Moreso F, Pons M, et al. High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients. J Am Soc Nephrol 2013; 24:487.
  98. Teo KK, Basile C, Ulan RA, et al. Comparison of hemodialysis and hypertonic hemodiafiltration on cardiac function [corrected]. Kidney Int 1987; 32:399.
  99. Santoro A, Mancini E, Bolzani R, et al. The effect of on-line high-flux hemofiltration versus low-flux hemodialysis on mortality in chronic kidney failure: a small randomized controlled trial. Am J Kidney Dis 2008; 52:507.
  100. Vilar E, Fry AC, Wellsted D, et al. Long-term outcomes in online hemodiafiltration and high-flux hemodialysis: a comparative analysis. Clin J Am Soc Nephrol 2009; 4:1944.
  101. Kuhlmann MK. On-line hemodiafiltration: not a self-fulfilling prophecy. J Am Soc Nephrol 2012; 23:974.
  102. Ok E, Asci G, Toz H, et al. Mortality and cardiovascular events in online haemodiafiltration (OL-HDF) compared with high-flux dialysis: results from the Turkish OL-HDF Study. Nephrol Dial Transplant 2013; 28:192.
  103. Blankestijn PJ. Haemodiafiltration: becoming the new standard? Nephrol Dial Transplant 2013; 28:1.
  104. Susantitaphong P, Jaber BL. Understanding discordant meta-analyses of convective dialytic therapies for chronic kidney failure. Am J Kidney Dis 2014; 63:888.
  105. Nistor I, Palmer SC, Craig JC, et al. Haemodiafiltration, haemofiltration and haemodialysis for end-stage kidney disease. Cochrane Database Syst Rev 2015; :CD006258.
  106. Mostovaya IM, Blankestijn PJ, Bots ML, et al. Clinical evidence on hemodiafiltration: a systematic review and a meta-analysis. Semin Dial 2014; 27:119.
  107. Canaud B, Bayh I, Marcelli D, et al. Improved survival of incident patients with high-volume haemodiafiltration: a propensity-matched cohort study with inverse probability of censoring weighting. Nephron 2015; 129:179.
  108. National Kidney Foundation. KDOQI Clinical Practice Guideline for Hemodialysis Adequacy: 2015 update. Am J Kidney Dis 2015; 66:884.
  109. ERA-EDTA Registry. Annual Report 2013. ERA-EDTA Registry 2015. http://www.era-edta-reg.org/files/annualreports/pdf/AnnRep2013.pdf (Accessed on November 03, 2015).
  110. ANZDATA. ANZDATA Registry 47th Annual Report. ANZDATA 2015. http://www.anzdata.org.au/anzdata/AnzdataReport/37thReport/c04_haemodialysis_v2.0_20150729.pdf (Accessed on November 03, 2015).
  111. Friedman EA. Birth and agony of hemofiltration. Am J Kidney Dis 2005; 45:603.
  112. Lévesque R, Marcelli D, Cardinal H, et al. Cost-Effectiveness Analysis of High-Efficiency Hemodiafiltration Versus Low-Flux Hemodialysis Based on the Canadian Arm of the CONTRAST Study. Appl Health Econ Health Policy 2015; 13:647.
  113. Mazairac AH, Blankestijn PJ, Grooteman MP, et al. The cost-utility of haemodiafiltration versus haemodialysis in the Convective Transport Study. Nephrol Dial Transplant 2013; 28:1865.
  114. Blankestijn PJ. Has the time now come to more widely accept hemodiafiltration in the United States? J Am Soc Nephrol 2013; 24:332.
  115. Leypoldt JK, Jaber BL, Lysaght MJ, et al. Kinetics and dosing predictions for daily haemofiltration. Nephrol Dial Transplant 2003; 18:769.
  116. Lopot F, Válek A. Time-averaged concentration--time-averaged deviation: a new concept in mathematical assessment of dialysis adequacy. Nephrol Dial Transplant 1988; 3:846.
  117. Gotch FA. The current place of urea kinetic modelling with respect to different dialysis modalities. Nephrol Dial Transplant 1998; 13 Suppl 6:10.
  118. Yamashita AC, Kawanishi H. Kinetics and dose of daily hemofiltration. Blood Purif 2004; 22 Suppl 2:14.
  119. Maduell F, Navarro V, Torregrosa E, et al. Change from three times a week on-line hemodiafiltration to short daily on-line hemodiafiltration. Kidney Int 2003; 64:305.
  120. Zimmerman DL, Swedko PJ, Posen GA, Burns KD. Daily hemofiltration with a simplified method of delivery. ASAIO J 2003; 49:426.
  121. Jaber BL, Zimmerman DL, Teehan GS, et al. Daily hemofiltration for end-stage renal disease: a feasibility and efficacy trial. Blood Purif 2004; 22:481.
  122. Fischbach M, Terzic J, Laugel V, et al. Daily on-line haemodiafiltration: a pilot trial in children. Nephrol Dial Transplant 2004; 19:2360.
  123. Zimmeman DL, Swedko P, Psen G, Burns K. Daily hemofiltration with a simplified method of delivery. J Am Soc Nephrol 2002; 13:61A.
  124. Fischbach M, Terzic J, Menouer S, et al. Daily on line haemodiafiltration promotes catch-up growth in children on chronic dialysis. Nephrol Dial Transplant 2010; 25:867.
  125. Lewin AJ, Greenbaum MA, Gordon A, Maxwell MH. Current status of the clinical application of the Redy R dialysate delivery system. Proc Clin Dial Transplant Forum 1972; 2:52.
  126. Ash SR. The Allient dialysis system. Semin Dial 2004; 17:164.
  127. Winchester JF. Sorbent hemoperfusion in end-stage renal disease: an in-depth review. Adv Ren Replace Ther 2002; 9:19.
  128. Winchester JF, Salsberg JA. Sorbents in the treatment of renal failure. Minerva Urol Nefrol 2004; 56:215.
  129. Kutsuki H. beta(2)-Microglobulin-selective direct hemoperfusion column for the treatment of dialysis-related amyloidosis. Biochim Biophys Acta 2005; 1753:141.
  130. Tsuda K, Taniguchi T. Effects of extracorporeal treatment with Lixelle on the mortality and inflammatory responses to endotoxin-induced shock in rats. Ther Apher Dial 2006; 10:49.
  131. Yatzidis H, Oreopoulos D. Early clinical trials with sorbents. Kidney Int Suppl 1976; :S215.
  132. Yatzidis H, Koutsicos D, Digenis P. Newer oral sorbents in uremia. Clin Nephrol 1979; 11:105.
  133. Friedman EA. Bowel as a kidney substitute in renal failure. Am J Kidney Dis 1996; 28:943.
  134. Fissell WH, Lou L, Abrishami S, et al. Bioartificial kidney ameliorates gram-negative bacteria-induced septic shock in uremic animals. J Am Soc Nephrol 2003; 14:454.
  135. Tumlin J, Wali R, Williams W, et al. Efficacy and safety of renal tubule cell therapy for acute renal failure. J Am Soc Nephrol 2008; 19:1034.
  136. Chertow GM, Waikar SS. Toward the promise of renal replacement therapy. J Am Soc Nephrol 2008; 19:839.
  137. Humes HD, Buffington D, Westover AJ, et al. The bioartificial kidney: current status and future promise. Pediatr Nephrol 2014; 29:343.
  138. Kim S, Fissell WH, Humes DH, Roy S. Current strategies and challenges in engineering a bioartificial kidney. Front Biosci (Elite Ed) 2015; 7:215.
  139. Song JJ, Guyette JP, Gilpin SE, et al. Regeneration and experimental orthotopic transplantation of a bioengineered kidney. Nat Med 2013; 19:646.
  140. Gura V, Beizai M, Ezon C, Rambod E. Continuous renal replacement therapy for congestive heart failure: the wearable continuous ultrafiltration system. ASAIO J 2006; 52:59.
  141. Davenport A, Gura V, Ronco C, et al. A wearable haemodialysis device for patients with end-stage renal failure: a pilot study. Lancet 2007; 370:2005.
  142. Gura V, Ronco C, Davenport A. The wearable artificial kidney, why and how: from holy grail to reality. Semin Dial 2009; 22:13.
  143. Gura V, Davenport A, Beizai M, et al. Beta2-microglobulin and phosphate clearances using a wearable artificial kidney: a pilot study. Am J Kidney Dis 2009; 54:104.
  144. Armignacco P, Garzotto F, Neri M, et al. Wak engineering evolution. Blood Purif 2015; 39:110.
  145. Nissenson AR, Ronco C, Pergamit G, et al. Continuously functioning artificial nephron system: the promise of nanotechnology. Hemodial Int 2005; 9:210.
  146. Nissenson AR. Bottom-up nanotechnology: the human nephron filter. Semin Dial 2009; 22:661.